Cargando…

Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer

Chromosome 17 alterations are found in more cancers than those of any other chromosome, and frequently involve the p53 gene on 17p13. The aim of this study was to identify the correlations between the presence of loss of heterozygosity (LOH) and microsatellite instability (MI) on chromosome 17p13 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Harima, Y, Shirahama, S, Harima, K, Aoki, S, Ohnishi, T, Tanaka, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374353/
https://www.ncbi.nlm.nih.gov/pubmed/10487620
http://dx.doi.org/10.1038/sj.bjc.6690658
_version_ 1782154433477476352
author Harima, Y
Shirahama, S
Harima, K
Aoki, S
Ohnishi, T
Tanaka, Y
author_facet Harima, Y
Shirahama, S
Harima, K
Aoki, S
Ohnishi, T
Tanaka, Y
author_sort Harima, Y
collection PubMed
description Chromosome 17 alterations are found in more cancers than those of any other chromosome, and frequently involve the p53 gene on 17p13. The aim of this study was to identify the correlations between the presence of loss of heterozygosity (LOH) and microsatellite instability (MI) on chromosome 17p13 in patients with cervical cancer and the patients’ response to radiotherapy. A total of 50 patients were treated with definitive radiotherapy. We performed biopsies and took specimens from the tumour and venous blood of all patients. Tumour and normal DNAs were analysed by polymerase chain reaction for genetic losses and instability at three polymorphic microsatellite loci mapped to 17p13. Nineteen of the 50 tumours (38%) displayed a genetic alteration (GA) on 17p13, 16 (32%) were found to have LOH, and three (6%) showed MI. The sizes of the tumours of the GA-positive patients were significantly greater than those of the GA-negative patients (P = 0.009). The mean tumour diameter of all patients was 6 ± 2.4 cm. We divided the patients into those with tumours smaller than 6 cm in diameter (n = 26) and those with tumours equal to or greater than 6 cm in diameter (n = 24). The former group survived significantly longer compared to the latter group (P = 0.0002). Among the patients with < 6 cm tumours, all six GA-positive patients are alive with no evidence of disease (NED), whereas of the 20 GA-negative patients, 18 have NED and two are alive with disease (AWD) or suffered cancer-caused death (CD). Thus, there was no correlation between GA and radiotherapy response in the tumours smaller than 6 cm. However, among the patients with ≥ 6 cm tumours, two of the GA-positive patients have NED and 11 are AWD/CD, whereas seven of the GA-negative patients have NED and four are AWD/CD. Among the patients with ≥ 6 cm tumours, the response to radiotherapy of the GA-positive patients were significantly poorer than those of the GA-negative patients (P = 0.02). In addition, the GA-negative patients survived significantly longer compared to the GA-positive patients (P = 0.026). The results of this study suggest that GA increases with tumour growth. Improved success in the management of bulky cervical cancer requires a better understanding of its biological behaviour. © 1999 Cancer Research Campaign
format Text
id pubmed-2374353
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23743532009-09-10 Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer Harima, Y Shirahama, S Harima, K Aoki, S Ohnishi, T Tanaka, Y Br J Cancer Regular Article Chromosome 17 alterations are found in more cancers than those of any other chromosome, and frequently involve the p53 gene on 17p13. The aim of this study was to identify the correlations between the presence of loss of heterozygosity (LOH) and microsatellite instability (MI) on chromosome 17p13 in patients with cervical cancer and the patients’ response to radiotherapy. A total of 50 patients were treated with definitive radiotherapy. We performed biopsies and took specimens from the tumour and venous blood of all patients. Tumour and normal DNAs were analysed by polymerase chain reaction for genetic losses and instability at three polymorphic microsatellite loci mapped to 17p13. Nineteen of the 50 tumours (38%) displayed a genetic alteration (GA) on 17p13, 16 (32%) were found to have LOH, and three (6%) showed MI. The sizes of the tumours of the GA-positive patients were significantly greater than those of the GA-negative patients (P = 0.009). The mean tumour diameter of all patients was 6 ± 2.4 cm. We divided the patients into those with tumours smaller than 6 cm in diameter (n = 26) and those with tumours equal to or greater than 6 cm in diameter (n = 24). The former group survived significantly longer compared to the latter group (P = 0.0002). Among the patients with < 6 cm tumours, all six GA-positive patients are alive with no evidence of disease (NED), whereas of the 20 GA-negative patients, 18 have NED and two are alive with disease (AWD) or suffered cancer-caused death (CD). Thus, there was no correlation between GA and radiotherapy response in the tumours smaller than 6 cm. However, among the patients with ≥ 6 cm tumours, two of the GA-positive patients have NED and 11 are AWD/CD, whereas seven of the GA-negative patients have NED and four are AWD/CD. Among the patients with ≥ 6 cm tumours, the response to radiotherapy of the GA-positive patients were significantly poorer than those of the GA-negative patients (P = 0.02). In addition, the GA-negative patients survived significantly longer compared to the GA-positive patients (P = 0.026). The results of this study suggest that GA increases with tumour growth. Improved success in the management of bulky cervical cancer requires a better understanding of its biological behaviour. © 1999 Cancer Research Campaign Nature Publishing Group 1999-09 /pmc/articles/PMC2374353/ /pubmed/10487620 http://dx.doi.org/10.1038/sj.bjc.6690658 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Harima, Y
Shirahama, S
Harima, K
Aoki, S
Ohnishi, T
Tanaka, Y
Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
title Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
title_full Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
title_fullStr Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
title_full_unstemmed Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
title_short Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
title_sort genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374353/
https://www.ncbi.nlm.nih.gov/pubmed/10487620
http://dx.doi.org/10.1038/sj.bjc.6690658
work_keys_str_mv AT harimay geneticalterationsonchromosome17passociatedwithresponsetoradiotherapyinbulkycervicalcancer
AT shirahamas geneticalterationsonchromosome17passociatedwithresponsetoradiotherapyinbulkycervicalcancer
AT harimak geneticalterationsonchromosome17passociatedwithresponsetoradiotherapyinbulkycervicalcancer
AT aokis geneticalterationsonchromosome17passociatedwithresponsetoradiotherapyinbulkycervicalcancer
AT ohnishit geneticalterationsonchromosome17passociatedwithresponsetoradiotherapyinbulkycervicalcancer
AT tanakay geneticalterationsonchromosome17passociatedwithresponsetoradiotherapyinbulkycervicalcancer